Talia Golan1, Alex Barenboim2, Guy Lahat2, Ido Nachmany2, Yacov Goykhman2, Einat Shacham-Shmueli1, Naama Halpern1, Eli Brazowski3, Ravit Geva4, Ido Wolf4, Yuri Goldes5, Menahem Ben-Haim6, Joseph M Klausner2, Nir Lubezky7. 1. Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel. 2. Liver Surgery Unit, Department of Surgery, Tel-Aviv Medical Center, Tel Aviv, Israel. 3. Institute of Pathology, Tel-Aviv Medical Center, Tel Aviv, Israel. 4. Institute of Oncology, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel. 5. Department of Surgery, Sheba Medical Center, The Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel. 6. Department of Surgery, Shaarey Zedek Medical Center, Jerusalem, Israel. 7. Liver Surgery Unit, Department of Surgery, Tel-Aviv Medical Center, Tel Aviv, Israel. nirl@tlvmc.gov.il.
Abstract
BACKGROUND: Neoadjuvant FOLFIRINOX is a standard-of-care treatment for BRPC patients. Patients with gBRCAm who have demonstrated improved response to platinum-based chemotherapy may have impaired homologous repair deficiency. This study aimed to describe the pathologic complete response rate and long-term survival for patients with germline BRCA1 or BRCA2 mutation (gBRCAm) and borderline resectable pancreatic cancer (BRPC) treated with neoadjuvant FOLFIRINOX. METHODS: A dual-center retrospective analysis was performed. Patients who had BRPC treated with neoadjuvant FOLFIRINOX followed by curative resection were identified from clinical databases. Pathologic complete response was defined as no viable tumor cells present in the specimen. Common founder Jewish germline BRCA1 or BRCA2 mutation was determined for available patients. RESULTS: The 61 BRPC patients in this study underwent resection after neoadjuvant FOLFIRINOX. Analysis of BRCA mutation was performed for 39 patients, and 9 patients were found to be BRCA2 germline mutation carriers. The pathologic complete response rate was 44.4% for the gBRCAm patients and 10% for the BRCA non-carriers (p = 0.009). The median disease-free survival was not reached for the gBRCAm patients and was 7 months for the BRCA non-carriers (p = 0.03). The median overall survival was not reached for the gBRCAm patients and was 32 months for the BRCA non-carriers (p = 0.2). After a mean follow-up period of 33.7 months, all eight patients with pathologic complete response were disease-free. CONCLUSIONS: The study showed that gBRCAm patients with BRPC have an increased chance for pathologic complete response and prolonged survival after neoadjuvant FOLFIRINOX. The results support the benefit of exposing gBRCAm patients to platinum-based chemotherapy early in the course of the disease. Neoadjuvant FOLFIRINOX should be considered for BRCA carriers who have resectable pancreatic cancer.
BACKGROUND: Neoadjuvant FOLFIRINOX is a standard-of-care treatment for BRPC patients. Patients with gBRCAm who have demonstrated improved response to platinum-based chemotherapy may have impaired homologous repair deficiency. This study aimed to describe the pathologic complete response rate and long-term survival for patients with germline BRCA1 or BRCA2 mutation (gBRCAm) and borderline resectable pancreatic cancer (BRPC) treated with neoadjuvant FOLFIRINOX. METHODS: A dual-center retrospective analysis was performed. Patients who had BRPC treated with neoadjuvant FOLFIRINOX followed by curative resection were identified from clinical databases. Pathologic complete response was defined as no viable tumor cells present in the specimen. Common founder Jewish germline BRCA1 or BRCA2 mutation was determined for available patients. RESULTS: The 61 BRPC patients in this study underwent resection after neoadjuvant FOLFIRINOX. Analysis of BRCA mutation was performed for 39 patients, and 9 patients were found to be BRCA2 germline mutation carriers. The pathologic complete response rate was 44.4% for the gBRCAm patients and 10% for the BRCA non-carriers (p = 0.009). The median disease-free survival was not reached for the gBRCAm patients and was 7 months for the BRCA non-carriers (p = 0.03). The median overall survival was not reached for the gBRCAm patients and was 32 months for the BRCA non-carriers (p = 0.2). After a mean follow-up period of 33.7 months, all eight patients with pathologic complete response were disease-free. CONCLUSIONS: The study showed that gBRCAm patients with BRPC have an increased chance for pathologic complete response and prolonged survival after neoadjuvant FOLFIRINOX. The results support the benefit of exposing gBRCAm patients to platinum-based chemotherapy early in the course of the disease. Neoadjuvant FOLFIRINOX should be considered for BRCA carriers who have resectable pancreatic cancer.
Authors: Matthew F Kalady; Luiz Felipe de Campos-Lobato; Luca Stocchi; Daniel P Geisler; David Dietz; Ian C Lavery; Victor W Fazio Journal: Ann Surg Date: 2009-10 Impact factor: 12.969
Authors: Toni T Seppälä; Jacquelyn W Zimmerman; Reecha Suri; Haley Zlomke; Gabriel D Ivey; Annamaria Szabolcs; Christopher R Shubert; John L Cameron; William R Burns; Kelly J Lafaro; Jin He; Christopher L Wolfgang; Ying S Zou; Lei Zheng; David A Tuveson; James R Eshlemann; David P Ryan; Alec C Kimmelman; Theodore S Hong; David T Ting; Elizabeth M Jaffee; Richard A Burkhart Journal: Clin Cancer Res Date: 2022-08-02 Impact factor: 13.801
Authors: James M Cleary; Brian M Wolpin; Stephanie K Dougan; Srivatsan Raghavan; Harshabad Singh; Brandon Huffman; Nilay S Sethi; Jonathan A Nowak; Geoffrey I Shapiro; Andrew J Aguirre; Alan D D'Andrea Journal: Clin Cancer Res Date: 2021-07-20 Impact factor: 13.801
Authors: R Casolino; C Braconi; G Malleo; S Paiella; C Bassi; M Milella; S B Dreyer; F E M Froeling; D K Chang; A V Biankin; T Golan Journal: Ann Oncol Date: 2020-11-26 Impact factor: 32.976